

REMINDER OF CLOSING DATE FOR NON-RENOUNCEABLE RIGHTS OFFER

MELBOURNE, Australia, 26 May 2023: Dimerix Limited (ASX: DXB) (**Dimerix** or the **Company**), a clinical-stage biopharmaceutical company advises eligible Shareholders that the Closing Date for the partially underwritten non-renounceable rights offer ("Rights Offer") is this coming Monday, 29 May 2023.

Further information is set out in a letter to shareholders which is attached to this release.

For further information, please visit our website at <https://dimerix.com/> or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [LinkedIn](#) and [Twitter](#)

Authorised for lodgement by the Board of the Company

—END—

SHAREHOLDER LETTER

Dear fellow shareholders,

As you will be aware from the announcement to the ASX on Wednesday 4th May 2023, Dimerix is conducting a non-renounceable rights issue for all eligible shareholders on the basis of 1 new Dimerix share for every 3 existing shares held at 7.00pm (Melbourne time) on 9 May 2023, at a price of \$0.08 per new share (see Prospectus dated 4 May 2023 for details). This represented a 17.5% discount to the closing price of shares on 28 April 2023 (being the last trading day before announcement of the rights issue), and a 21.1% discount to the 5-day VWAP up to and including 28 April 2023. If fully subscribed, the rights issue would raise \$8.56 million before costs of the issue. The rights issue is partially underwritten as set out in the Prospectus.

Despite the downturn in global biotech markets, and the subsequent downward impact on our own share price, this rights issue provides existing shareholders with an opportunity as Dimerix continues to progress its global Phase 3 FSGS clinical study and move closer towards partnering and potential marketing approval.

Proceeds from the rights issue will be used to continue advancement of our exciting Phase 3 clinical program which is expected to see first interim data in Q1 2024, as well as activities seeking to attract potential new partners for a disease that has no approved products.

Those eligible shareholders participating in the rights issue will also receive two (2) free attaching options (one of each class) for every two shares under the rights issue, options being described below:

- One (1) unlisted option with an exercise price of \$0.126 (12.6 cents) and expiry date of 31 March 2024 (Short Term New Options); and
- One (1) option with an exercise price of \$0.154 (15.4 cents) and expiry date of 30 June 2025 (Long Term New Options). The Company proposes seeking quotation (listing) of the Long Term New Options, subject to meeting quotation requirements of ASX.

It really is worth reminding ourselves that we are all invested in a company which is at the forefront of delivering a new potential treatment for this rare type of kidney disease. Patients with FSGS today face poor outcomes with limited medical options. If successful, our drug candidate could make a huge difference globally to patients with this progressive and serious illness and given we have orphan drug designation status, a potential fast track to commercialisation is available - highlighting the compelling nature of this trial for the Company.

Thank you to those shareholders who have already subscribed for their entitlement (and shortfall, as applicable). For those who have not but intend on doing so, please be aware that

the offer closes on **Monday 29th May at 5pm.**

Please read the prospectus which can be obtained on Dimerix' website (details on the following page) carefully before deciding to accept your entitlement. A copy of your personalised entitlement and application form can be downloaded using the details which were previously sent to you, or as set out on the following page.

To all our shareholders, thank you for your continued patience and support.

Dr Nina Webster
CEO & Managing Director

A copy of the Prospectus is available to view on the ASX website and Dimerix' website at:

<https://investors.dimerix.com/investor-centre/?page=corporate-governance>.

Shareholders should read the Prospectus in full prior to making an application under the rights issue offer. Your application under the Offer must be made by making payment in accordance with the personalised payment instructions on your Entitlement and Acceptance Form.

Shareholders can also download their Entitlement and Acceptance Form using the below three choices:

I already have an online account with the Automic Share registry	https://investor.automic.com.au Select: "Existing Users Sign In". Once you have successfully signed in, click on "Documents and Statements". Download the Prospectus and Entitlement and Acceptance form.
I don't have an online account with Automic – but wish to register for one	https://investor.automic.com.au/#/signup Select: Dimerix Limited from the dropdown list in the ISSUER field. Enter you holder number SRN / HIN (from your latest Holding Statement). Enter Postcode (Aust only) or Country of Residence (if not Australia). Tick box "I am not a robot", then Next Complete prompts. Once you have successfully signed in, click on "Documents and Statements". Download the Prospectus and Entitlement and Acceptance form.
I don't have an online account with Automic – but want to use Automic for this Offer only	https://investor.automic.com.au/#/loginsah Select: Dimerix Limited from the dropdown list in the ISSUER field. Enter you holder number SRN / HIN (from your latest Holding Statement). Enter Postcode (Aust only) or Country of Residence (if not Australia). Tick box "I am not a robot", then Access. Once you have successfully signed in, click on "Documents and Statements". Download the Prospectus and Entitlement and Acceptance form.

The rights issue closes at 5:00 pm (Melbourne time) on Monday 29 May 2023.

Offers of Dimerix Ltd's shares and options are made in the Prospectus dated 4 May 2023 which has been lodged with the Australian Securities and Investments Commission and ASX Limited.

Anyone who is eligible to participate in the rights issue who wishes to acquire Dimerix Ltd's shares will need to complete an application accompany the Prospectus as described above. Before deciding to acquire shares, you should read and consider the Prospectus in its entirety and, if any doubt, consult with your professional advisor.